A population-based analysis of surgical and adjuvant therapy for resected gastric cancer: Are patients receiving appropriate treatment following publication of the intergroup 0116 results?

Charles Enestvedt, Brian S. Diggs, Donald K. Shipley, Charles Thomas, Kevin Billingsley

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

BACKGROUND: The use of adjuvant therapy for resectable gastric adeno-carcinoma has become standard of care since the publication of the Intergroup 0116 data. The aims of this study were to (1) assess current practice patterns in gastric cancer treatment, and (2) determine the effect of increasing use of adjuvant chemoradiotherapy on survival in patients with gastric cancer. PATIENTS AND METHODS: Data from the Oregon State Cancer Registry were abstracted for demographics, disease stage, resection type, number of lymph nodes resected, adjuvant chemoradiotherapy (CRT), and survival for 1996-2006. Patients with stages IB-III disease were divided into cohorts treated through year 2001 (Group 1) or after 2001 (Group 2). Chemoradiotherapy use between groups was compared with the chi-square test. Univariate and multivariate analyses of survival were performed. Binary logistic regression determined predictors for the receipt of CRT. RESULTS: A total of 308 patients met study criteria. Adjuvant therapy was employed in 17.0% of cases in Group 1 vs. 36.8% in Group 2 (P

Original languageEnglish (US)
Pages (from-to)27-32
Number of pages6
JournalGastrointestinal Cancer Research
Volume3
Issue number6
StatePublished - Nov 2010

Fingerprint

Adjuvant Chemoradiotherapy
Stomach Neoplasms
Publications
Chemoradiotherapy
Survival
Population
Chi-Square Distribution
Standard of Care
Registries
Stomach
Therapeutics
Multivariate Analysis
Logistic Models
Lymph Nodes
Demography
Carcinoma
Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Gastroenterology

Cite this

@article{cbe0f3351f4d4a3cb7de0acffe490d37,
title = "A population-based analysis of surgical and adjuvant therapy for resected gastric cancer: Are patients receiving appropriate treatment following publication of the intergroup 0116 results?",
abstract = "BACKGROUND: The use of adjuvant therapy for resectable gastric adeno-carcinoma has become standard of care since the publication of the Intergroup 0116 data. The aims of this study were to (1) assess current practice patterns in gastric cancer treatment, and (2) determine the effect of increasing use of adjuvant chemoradiotherapy on survival in patients with gastric cancer. PATIENTS AND METHODS: Data from the Oregon State Cancer Registry were abstracted for demographics, disease stage, resection type, number of lymph nodes resected, adjuvant chemoradiotherapy (CRT), and survival for 1996-2006. Patients with stages IB-III disease were divided into cohorts treated through year 2001 (Group 1) or after 2001 (Group 2). Chemoradiotherapy use between groups was compared with the chi-square test. Univariate and multivariate analyses of survival were performed. Binary logistic regression determined predictors for the receipt of CRT. RESULTS: A total of 308 patients met study criteria. Adjuvant therapy was employed in 17.0{\%} of cases in Group 1 vs. 36.8{\%} in Group 2 (P",
author = "Charles Enestvedt and Diggs, {Brian S.} and Shipley, {Donald K.} and Charles Thomas and Kevin Billingsley",
year = "2010",
month = "11",
language = "English (US)",
volume = "3",
pages = "27--32",
journal = "Gastrointestinal Cancer Research",
issn = "1934-7820",
publisher = "International Society of Gastrointestinal Oncology",
number = "6",

}

TY - JOUR

T1 - A population-based analysis of surgical and adjuvant therapy for resected gastric cancer

T2 - Are patients receiving appropriate treatment following publication of the intergroup 0116 results?

AU - Enestvedt, Charles

AU - Diggs, Brian S.

AU - Shipley, Donald K.

AU - Thomas, Charles

AU - Billingsley, Kevin

PY - 2010/11

Y1 - 2010/11

N2 - BACKGROUND: The use of adjuvant therapy for resectable gastric adeno-carcinoma has become standard of care since the publication of the Intergroup 0116 data. The aims of this study were to (1) assess current practice patterns in gastric cancer treatment, and (2) determine the effect of increasing use of adjuvant chemoradiotherapy on survival in patients with gastric cancer. PATIENTS AND METHODS: Data from the Oregon State Cancer Registry were abstracted for demographics, disease stage, resection type, number of lymph nodes resected, adjuvant chemoradiotherapy (CRT), and survival for 1996-2006. Patients with stages IB-III disease were divided into cohorts treated through year 2001 (Group 1) or after 2001 (Group 2). Chemoradiotherapy use between groups was compared with the chi-square test. Univariate and multivariate analyses of survival were performed. Binary logistic regression determined predictors for the receipt of CRT. RESULTS: A total of 308 patients met study criteria. Adjuvant therapy was employed in 17.0% of cases in Group 1 vs. 36.8% in Group 2 (P

AB - BACKGROUND: The use of adjuvant therapy for resectable gastric adeno-carcinoma has become standard of care since the publication of the Intergroup 0116 data. The aims of this study were to (1) assess current practice patterns in gastric cancer treatment, and (2) determine the effect of increasing use of adjuvant chemoradiotherapy on survival in patients with gastric cancer. PATIENTS AND METHODS: Data from the Oregon State Cancer Registry were abstracted for demographics, disease stage, resection type, number of lymph nodes resected, adjuvant chemoradiotherapy (CRT), and survival for 1996-2006. Patients with stages IB-III disease were divided into cohorts treated through year 2001 (Group 1) or after 2001 (Group 2). Chemoradiotherapy use between groups was compared with the chi-square test. Univariate and multivariate analyses of survival were performed. Binary logistic regression determined predictors for the receipt of CRT. RESULTS: A total of 308 patients met study criteria. Adjuvant therapy was employed in 17.0% of cases in Group 1 vs. 36.8% in Group 2 (P

UR - http://www.scopus.com/inward/record.url?scp=77958106052&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77958106052&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:77958106052

VL - 3

SP - 27

EP - 32

JO - Gastrointestinal Cancer Research

JF - Gastrointestinal Cancer Research

SN - 1934-7820

IS - 6

ER -